Business
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026Idorsia Ltd (SIX: IDIA) announces an exclusive license and supply agreement with EMS S.A., Brazil’s largest privately-owned pharmaceutical company, to bring QUVIVIQ™ (daridorexant) to patients across Latin America. This partnership marks another milestone in Idorsia’s mission to make QUVIVIQ available worldwide
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":103,"olType":false},{"type":"text","content":"Allschwil, Switzerland – January 28, 2026Idorsia Ltd (SIX: IDIA) announces an exclusive license and supply agreement with EMS S.A., Brazil’s largest privately-owned pharmaceutical company, to bring QUVIVIQ™ (daridorexant) to patients across Latin America. This partnership marks another milestone in Idorsia’s mission to make QUVIVIQ available worldwide.","length":355,"tagName":"p"},{"type":"text","content":"Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: “We are very excited to join forces with EMS, a market leader with exceptional commercial reach and expertise. This collaboration is a strategic step forward in our global expansion, ensuring that patients in Latin America will soon have access to our innovative treatment for insomnia – the only medication to have shown improvement on daytime functioning and treat insomnia as a 24-hour disorder. Together, we aim to transform the nights and days for millions of people struggling with this condition.”","length":571,"tagName":"p"},{"type":"text","content":"Under the licensing and supply agreement, EMS will be responsible for the registration and commercialization of QUVIVIQ in Latin America. The filing of a regulatory dossier with ANVISA to obtain marketing authorization in Brazil took place in 2025. Idorsia is entitled to receive:","length":280,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total milestone compensation of USD 20 million for the execution ...